EA-230 is a newly developed synthetic compound with anti-inflammatory properties.
Pre-clinical data indicate that EA-230 may be a valuable treatment for systemic inflammation
resulting from a variety of causes such as surgery, trauma, infection, irradiation and
others. Although previous studies in healthy volunteers have shown an excellent safety
profile, the safety and tolerability of higher doses administered per continuous infusion
need to be investigated. Also, the dose-effect relation on systemic inflammation needs to be
further elucidated before a phase II trial in patients can be commenced.